PT - JOURNAL ARTICLE AU - 4C Initiative of the CVD-COVID-UK consortium AU - S Ball AU - A Banerjee AU - C Berry AU - J Boyle AU - B Bray AU - W Bradlow AU - A Chaudhry AU - R Crawley AU - J Danesh AU - A Denniston AU - F Falter AU - JD Figueroa AU - C Hall AU - H Hemingway AU - E Jefferson AU - T Johnson AU - G King AU - K Lee AU - P McKean AU - SM Mason AU - N Mills AU - E Pearson AU - M Pirmohamed AU - MTC Poon AU - R Priedon AU - A Shah AU - R Sofat AU - J Sterne AU - F Strachan AU - CLM Sudlow AU - Z Szarka AU - W Whiteley AU - M Wyatt TI - The 4C Initiative (Clinical Care for Cardiovascular disease in the COVID-19 pandemic) – monitoring the indirect impact of the coronavirus pandemic on services for cardiovascular diseases in the UK AID - 10.1101/2020.07.10.20151118 DP - 2020 Jan 01 TA - medRxiv PG - 2020.07.10.20151118 4099 - http://medrxiv.org/content/early/2020/07/11/2020.07.10.20151118.short 4100 - http://medrxiv.org/content/early/2020/07/11/2020.07.10.20151118.full AB - Background The coronavirus (COVID-19) pandemic affects cardiovascular diseases (CVDs) directly through infection and indirectly through health service reorganisation and public health policy. Real-time data are needed to quantify direct and indirect effects. We aimed to monitor hospital activity for presentation, diagnosis and treatment of CVDs during the pandemic to inform on indirect effects.Methods We analysed aggregate data on presentations, diagnoses and treatments or procedures for selected CVDs (acute coronary syndromes, heart failure, stroke and transient ischaemic attack, venous thromboembolism, peripheral arterial disease and aortic aneurysm) in UK hospitals before and during the COVID-19 epidemic. We produced an online visualisation tool to enable near real-time monitoring of trends.Findings Nine hospitals across England and Scotland contributed hospital activity data from 28 Oct 2019 (pre-COVID-19) to 10 May 2020 (pre-easing of lockdown), and for the same weeks during 2018-2019. Across all hospitals, total admissions and emergency department (ED) attendances decreased after lockdown (23 March 2020) by 57.9% (57.1-58.6%) and 52.9% (52.2-53.5%) respectively compared with the previous year. Activity for cardiac, cerebrovascular and other vascular conditions started to decline 1-2 weeks before lockdown, and fell by 31-88% after lockdown, with the greatest reductions observed for coronary artery bypass grafts, carotid endarterectomy, aortic aneurysm repair and peripheral arterial disease procedures. Compared with before the first UK COVID-19 (31 January 2020), activity declined across diseases and specialties between the first case and lockdown (total ED attendances RR 0.94, 0.93-0.95; total hospital admissions RR 0.96, 0.95-0.97) and after lockdown (attendances RR 0.63, 0.62-0.64; admissions RR 0.59, 0.57-0.60). There was limited recovery towards usual levels of some activities from mid-April 2020.Interpretation Substantial reductions in total and cardiovascular activities are likely to contribute to a major burden of indirect effects of the pandemic, suggesting they should be monitored and mitigated urgently.Funding British Heart Foundation, Health Data Research UKCompeting Interest StatementThe authors have declared no competing interest.Funding StatementColin Berry is supported by the British Heart Foundation (RE/18/6134217). Cathie Sudlow is supported by the British Heart Foundation and Health Data Research UK. Rouven Priedon is supported by the British Heart Foundation and Health Data Research UK. Munir Pirmohamed is supported by Health Data Research UK and the MRC Centre for Drug Safety Science. William Whiteley is supported by a Scottish Senior Fellowship from the Chief Scientist Office (CAF/17/01). John Danesh holds a British Heart Foundation Personal Chair and is supported by grants from the British Heart Foundation, Health Data Research UK, and the National Institute for Health Research. Afzal Chaudhry receives support from the Cambridge NIHR Biomedical Research Centre. Michael Poon is supported by Cancer Research UK.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:No IRB required but provision of data underwent local clinical governance approval.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesVisualisation of data is available in the web application. Raw data is not released because of data governance. http://hospitalactivity.com https://github.com/HDRUK/4C-Initiative